Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X:
“The NHS-Galleri trial reportedly failed its primary endpoint – a sobering reminder from Richard Sullivan and Dr. Christopher Booth in this editorial at JAMA that technological elegance is no substitute for proven patient benefit.”
Title: Multicancer Detection Tests. Promise, Hype, and Reality
Authors: Richard Sullivan, Christopher M. Booth
Other articles featuring Amol Akhade on OncoDaily.
